



Predicting the impact of genetic variants on protein stability and human health



Winter School - University of Verona
Canazei (TN)
January 17, 2019




Emidio Capriotti

<http://biofold.org/>



Biomolecules
Folding and
Disease



Department of Pharmacy
and Biotechnology (FaBiT)
University of Bologna

Single Nucleotide Variants

Single Nucleotide Variants (SNVs)

is a DNA sequence variation occurring when a single nucleotide A, T, C, or G in the genome differs between members of the species.


It is used to refer to Polymorphisms when the population frequency is $\geq 1\%$

SNVs occur at any position and can be classified on the base of their locations.

Coding SNVs can be subdivided into two groups:

Synonymous: when single base substitutions do not cause a change in the resultant amino acid


Non-synonymous or Single Amino Acid Variants (SAVs): when single base substitutions cause a change in the resultant amino acid.



Sequence, Structure & Function


Genomic variants in sequence motifs could affect protein function.

Mutation S362A of P53 affect the interaction with hydrolase USP7 and the deubiquitination of the protein.



Nonsynonymous variants responsible for protein structural changes and cause loss of stability of the folded protein.

Mutation R411L removes the salt bridge stabilizing the structure of the IVD dehydrogenase.




Machine learning

- Computational approach to build models based on the analysis of empirical data.
- Machine learning algorithms are suitable to address problems for which analytic solution does not exists and large amount of data are available.
- They are implemented selecting a representative set of data that are used in a training step and then validated on a test set with data “*not seen*” during the training.
- Most popular machine learning approaches are in computational biology are Neural Networks, Support Vector Machines and Random Forest.


Input and Output

A machine learning algorithm takes in input a set of variables (features) and returns a numerical or discrete output




Types of Predictions

- Regression is used to predict continuous values.



- Classification is used to predict which class a data point is part of (discrete value).



Regression Evaluation

Compare predicted and real values using different correlation tests
and the Root Mean Square Error

Pearson Correlation

$$r = \frac{\sum(x - \bar{x})(y - \bar{y})}{\sqrt{\sum(x - \bar{x})^2 \sum(y - \bar{y})^2}}$$

Root Mean Square Error

$$\text{RMSE} = \sqrt{\frac{\sum_{i=1}^n (P_i - O_i)^2}{n}}$$

Classification Evaluation

Overall Accuracy

$$Q2 = \frac{TP + TN}{TP + FN + TN + FP}$$

Sensitivity

$$S = \frac{TP}{TP + FN}$$

Precision

$$P = \frac{TP}{TP + FP}$$

Matthews Correlation

$$C = \frac{TP \times TN - FP \times FN}{\sqrt{(TP + FP) \times (TP + FN) \times (TN + FP) \times (TN + FN)}}$$

| | | Actual values | |
|-------------------------|----------|----------------------|----------|
| | | Positive | Negative |
| Predicted values | Positive | TP | FP |
| | Negative | FN | TN |

ROC Curve

True Positive Rate



$$TPR = \frac{TP}{TP + FN}$$

False Positive Rate

$$FPR = \frac{FP}{FP + TN}$$

The Area Under the Receiver operating characteristic (ROC) Curve (AUC) is a prediction evaluation measure that is 0.5 for completely random predictors and close to 1.0 for highly accurate predictors.


Baldi et al. (2000) Bioinformatics, 16:412-424



Mutation and Stability



Protein folding

Protein folding is the **process by which a protein assumes its native structure** from the unfolded structure



Folding and stability

The folding free energy difference, ΔG_f , is typically small, of the order of -5 to -15 kcal/mol for a globular protein (compared to e.g. -30 to -100 kcal/mol for a covalent bond).




Folding and mutations

- Mutations of the protein sequence can affect the folding process changing the stability of the folded structure.
- Failure to folding process can produce inactive proteins with different properties even toxic. Protein misfolding is believed to be the main cause of neurodegenerative and other diseases.
- Web available databases are collecting large amount of thermodynamic data from mutagenesis experiments that can be used to develop methods for the prediction the protein stability change upon mutation.

Mutation and stability


if a protein is mutated in a single site, what is the effect of the mutation on the stability of the protein?



Free energy change

If we mutate one residue in the protein sequence,
is the protein stability **increased or decreased?**


$$\Delta\Delta G_f = \Delta G_f^{\text{mut}} - \Delta G_f^{\text{wt}}$$




ProTherm database

ProTherm is a collection of numerical data of thermodynamic parameters including **Gibbs free energy change, enthalpy change, heat capacity change, transition temperature** etc. for wild type and mutant proteins, that are important for understanding the structure and stability of proteins.


| | |
|-----------------------------------|--------------|
| Total number of entries | 25820 |
| Number of unique proteins | 740 |
| Total number of all proteins | 1045 |
| Number of Proteins with mutants | 311 |
| Number of Single Mutations | 12561 |
| Number of Double Mutations | 1744 |
| Number of Multiple Mutations | 1132 |
| Number of Wild Type | 10383 |



Sequence-based predictor




SVM-SEQUENCE: 20 element vector that describes the amino acid mutation,
 2 element pH and T (experimental conditions)
 20 more input features (40 in total) encoding the sequence residue environment




■ Mutated Aminoacid

■ Sequence Window

Structure-based predictor



SVM-STRUCTURE: **20 element vector that describes the amino acid mutation,**
3 element pH, T and relative solvent accessible area
20 more input features (43 in total) encoding the structure residue environment



Mutated Aminoacid

$0 < R < 2\text{\AA}$


$2 < R < 4\text{\AA}$

$4 < R < 6\text{\AA}$

Classification results

| | Q2 | P[-] | S[-] | P[+] | S[+] | C |
|----------------------|------|------|------|------|------|------|
| SVM-Sequence | 0.77 | 0.79 | 0.91 | 0.69 | 0.46 | 0.42 |
| SVM-Structure | 0.80 | 0.83 | 0.91 | 0.73 | 0.56 | 0.51 |


+ Increase stability – Decrease stability



Q2: Overall Accuracy **C:** Mean Correlation Coefficient **DB:** Fraction of database that are predicted with a reliability \geq the given threshold

Regression results


Sequence-based predictor



DBSEQ= 2087 mutations

C= 0.62 (RMSE= 1.45 kcal/mole)

Structure-based predictor



DB3D= 1948 mutations

C= 0.71 (RMSE= 1.30 kcal/mole)

<http://folding.biofold.org/i-mutant>

Capriotti et al. (2005) Nucleic Acids Research 33, W306-W310.


Mutation and Disease

Personalized medicine

Currently direct to consumers company are performing genotype test on markers associated to genetic traits, and soon full genome sequencing will cost ~\$1000.

The future bioinformatics challenges for personalized medicine will be:

1. Processing Large-Scale Robust Genomic Data
2. Interpretation of the Functional Effect and the Impact of Genomic Variation
3. Integrating Systems and Data to Capture Complexity
4. Making it all clinically relevant



1000 Genomes

The 1000 Genomes Project aims to create the **largest public catalogue of human variations and genotype data**. Last versione released the genotype of ~2,500 individuals.

Table 1 | Variants discovered by project, type, population and novelty



a Summary of project data including combined exon populations

| Statistic | Low coverage | | | | Trios | | | Exon (total) | Union across projects |
|--|--------------------|---------------------|--------------------|---------------------|--------------------|--------------------|--------------------|-----------------|--------------------------|
| | CEU | YRI | CHB+JPT | Total | CEU | YRI | Total | | |
| Samples | 60 | 59 | 60 | 179 | 3 | 3 | 6 | 697 | 742 |
| Total raw bases (Gb) | 1,402 | 874 | 596 | 2,872 | 560 | 615 | 1,175 | 845 | 4,892 |
| Total mapped bases (Gb) | 817 | 596 | 468 | 1,881 | 369 | 342 | 711 | 56 | 2,648 |
| Mean mapped depth (×) | 4.62 | 3.42 | 2.65 | 3.56 | 43.14 | 40.05 | 41.60 | 55.92 | NA |
| Bases accessed (% of genome) | 2.43 Gb (86%) | 2.39 Gb (85%) | 2.41 Gb (85%) | 2.42 Gb (86.0%) | 2.26 Gb (79%) | 2.21 Gb (78%) | 2.24 Gb (79%) | 1.4 Mb | NA |
| No. of SNPs (% novel) | 7,943,827 (33%) | 10,938,130 (47%) | 6,273,441 (28%) | 14,894,361 (54%) | 3,646,764 (11%) | 4,502,439 (23%) | 5,907,699 (24%) | 12,758 (70%) | 15,275,256 (55%) |
| Mean variant SNP sites per individual | 2,918,623 | 3,335,795 | 2,810,573 | 3,019,909 | 2,741,276 | 3,261,036 | 3,001,156 | 763 | NA |
| No. of indels (% novel) | 728,075 (39%) | 941,567 (52%) | 666,639 (39%) | 1,330,158 (57%) | 411,611 (25%) | 502,462 (37%) | 682,148 (38%) | 96 (74%) | 1,480,877 (57%) |
| Mean variant indel sites per individual | 354,767 | 383,200 | 347,400 | 361,669 | 322,078 | 382,869 | 352,474 | 3 | NA |
| No. of deletions (% novel) | ND | ND | ND | 15,893 (60%) | 6,593 (41%) | 8,129 (50%) | 11,248 (51%) | ND | 22,025 (61%) |
| No. of genotyped deletions (% novel) | ND | ND | ND | 10,742 (57%) | ND | ND | 6,317 (48%) | ND | 13,826 (58%) |
| No. of duplications (% novel) | 259 (90%) | 320 (90%) | 280 (91%) | 407 (89%) | 187 (93%) | 192 (91%) | 256 (92%) | ND | 501 (89%) |
| No. of mobile element insertions (% novel) | 3,202 (79%) | 3,105 (84%) | 1,952 (76%) | 4,775 (86%) | 1,397 (68%) | 1,846 (78%) | 2,531 (78%) | ND | 5,370 (87%) |
| No. of novel sequence insertions (% novel) | ND | ND | ND | ND | 111 (96%) | 66 (86%) | 174 (93%) | ND | 174 (93%) |

SNVs and Disease


Single Nucleotide Variants (SNVs) are the most common type of genetic variations in human accounting for more than **90% of sequence differences** (1000 Genome Project Consortium, 2012).

SNVs can also be responsible of genetic diseases (Ng and Henikoff, 2002; Bell, 2004).



SNVs and SAVs databases

dbSNP (Mar 2018) @ NCBI



The screenshot shows the dbSNP homepage. At the top, there's a search bar with 'SNP' selected and a 'Search' button. Below the search bar is a 'Help' link. The main content area features a map of genetic variants and a brief description: 'Database of single nucleotide polymorphisms (SNPs) and multiple small-scale variations that include insertions/deletions, microsatellites, and non-polymorphic variants.' Below this are three main navigation sections: 'Getting Started' (Overview of dbSNP, dbSNP Handbook, FAQ, Factsheet), 'Submit Data' (Clinically Associated Human Variations, All Other Variations, Hold Until Published (HUP) Policies), and 'Access Data' (Web Search, Organism List, Batch Query, FTP Download).

<http://www.ncbi.nlm.nih.gov/snp>

SwissVar (Oct 2018) @ ExPASy



<http://www.expasy.ch/swissvar/>

Single Nucleotide Variants

| | |
|----------------------|--------------------|
| <i>Homo sapiens</i> | 113,862,023 |
| <i>Gallus gallus</i> | 15,104,956 |
| <i>Zea mays</i> | 14,672,946 |

Single Amino acid Variants

| | |
|----------------------|--------|
| <i>Homo sapiens</i> | 76,608 |
| <i>Disease</i> | 29,529 |
| <i>Polymorphisms</i> | 39,779 |

Conserved or not?

In positions 66 the Glutamic acid is highly conserved Asparagine in position 138 is mutated Threonine or Alanine

Sequence logo for the SLEAL domain:

| Position | A | T | C | G | Others |
|----------|-----|-----|-----|-----|---------|
| 1 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 (S) |
| 81 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 (R) |
| 160 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 (K) |


Phylogenetic tree (rooted at the bottom) showing the evolutionary relationships of the SLEAL domain across various species:

- Root (red)
- Group 1 (blue): P11686, P15783, P21841, P22398, Q1XFL5, UPI0000E219B8, UPI00005A47C8, Q3MSM1, Q95M82
- Group 2 (green): UPI000155957, B3DM51
- Group 3 (orange): UPI0001555957
- Group 4 (purple): UPI000155C160
- Group 5 (pink): UPI0001555957


Sequence profile

The protein **sequence profile** is calculated running **BLAST** on the UniRef90 dataset and selecting only the hits with $e\text{-value} < 10^{-9}$.


The **frequency distributions of the wild-type residues** for disease-related and neutral variants are significantly different (KS p-value=0).



SNPs&GO input features




Protein sequence profile information derived from a multiple sequence alignment. It is encoded in a 5 elements vector corresponding to different features general and local features



The GO information are encoded in a 2 elements vector corresponding to the number unique of GO terms associated to the protein sequences and the sum of the logarithm of the total number of disease-related and neutral variants for each GO term.

SNPs&GO performance

SNPs&GO results in better performance with respect to previously developed methods.




| Method | Q2 | P[D] | Q[D] | P[N] | Q[N] | C | PM |
|--------------------|------|------|------|------|------|------|-----|
| PolyPhen | 0,71 | 0,76 | 0,75 | 0,63 | 0,64 | 0,39 | 58 |
| SIFT | 0,76 | 0,75 | 0,76 | 0,77 | 0,75 | 0,52 | 93 |
| PANTHER | 0,74 | 0,77 | 0,73 | 0,71 | 0,76 | 0,48 | 76 |
| SNPs&GO | 0,82 | 0,83 | 0,78 | 0,80 | 0,85 | 0,63 | 100 |

D = Disease related N = Neutral

DB= 33672 nsSNVs



Structure environment

There is a **significant difference** (KS p-value = 2.8×10^{-71}) between the **distributions** of the relative Accessible Solvent Area for disease-related and neutral variants. Their mean values are respectively 20.6 and 35.7.



The structure-based method

The method takes in to input 4 types of information encoded in a 48 elements vector. The input features are: mutation data; structure environment, sequence profile and functional score based on GO terms.



Mutated Aminoacid

0 < R < 2 Å



2 < R < 4 Å

4 < R < 6 Å

Sequence vs Structure


The structure-based method results in better accuracy with respect to the sequence-based one. **Structure based prediction are 3% more accurate** and **correlation coefficient increases of 0.06**. If 10% of FP are accepted the TPR increases of 7%.

| | Q2 | P[D] | S[D] | P[N] | S[N] | C | AUC |
|---------------------------------|------|------|------|------|------|------|------|
| SNPs&GO | 0.82 | 0.81 | 0.83 | 0.82 | 0.81 | 0.64 | 0.89 |
| SNPs&GO^{3d} | 0.85 | 0.84 | 0.87 | 0.86 | 0.83 | 0.70 | 0.92 |



Accuracy vs Accessibility

The predictions are more accurate for mutations occurring in buried region (0-30%). Mutations of exposed residues results in lower accuracy.




Prediction example

Damaging missing Cys-Cys interaction in the Glycosylasparaginase. The mutation p.Cys163Ser results in the loss of the disulfide bridge between Cys163 and Cys179. This SAP is responsible for Aspartylglucosaminuria.




1APY: Chain A, Res: 2.0 Å



Whole-genome predictions

Most of the genetic variants occur in non-coding region that represents >98% of the whole genome.




Predict the effect of SNVs in non-coding region is a challenging task because conservation is more difficult to estimate.

Sequence alignment is more complicated for sequences from non-coding regions.


PhyloP100 score

Conservation analysis based on the pre-calculated score available at the UCSC revealed a **significant difference between the distribution of the PhyloP100 scores in Pathogenic and Benign SNVs.**



PhD-SNPG


PhD-SNPG is a simple method that takes in input **35 sequence-based features** from a window of 5 nucleotides around the mutated position.



Benchmarking

PhD-SNP^g has been tested in cross-validation on a set of 35,802 SNVs and on a blind set of 1,408 variants recently annotated.

| | Q2 | TNR | NPV | TPR | PPV | MCC | F1 | AUC |
|----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|
| PhD-SNP^g | 0.861 | 0.774 | 0.884 | 0.925 | 0.847 | 0.715 | 0.884 | 0.924 |
| Coding | 0.849 | 0.671 | 0.845 | 0.938 | 0.850 | 0.651 | 0.892 | 0.908 |
| Non-Coding | 0.876 | 0.855 | 0.911 | 0.901 | 0.839 | 0.753 | 0.869 | 0.930 |



Blind Validation

CAGI experiments

The Critical Assessment of Genome Interpretation is a community experiment to objectively assess computational methods for predicting the phenotypic impacts of genomic variation.

Hi emidio, welcome back.

• [Your account](#) • [Sign out](#)



[Home](#) [Data Use Agreement](#) [FAQ](#) [Organizers](#) [Contact](#) [CAGI 4](#) [Previous CAGIs](#)

CAGI 4

- ☒ [Overview](#)
- ☒ [CAGI Presentations](#)
- ☒ [Challenges](#)
 - ☒ [Bipolar exomes](#)
 - ☒ [Crohn's exomes](#)
 - ☒ [eQTL causal SNPs](#)
 - ☒ [Hopkins clinical panel](#)
 - ☒ [NAGLU](#)
 - ☒ [NPM-ALK](#)
 - ☒ [PGP](#)
 - ☒ [Pyruvate kinase](#)
 - ☒ [SickKids clinical genomes](#)
 - ☒ [SUMO ligase](#)
 - ☒ [Warfarin exomes](#)
- ☒ [Conference](#)

Welcome to the CAGI experiment!

The CAGI 4 Conference

The Fourth Critical Assessment of Genome Interpretation (CAGI 4) prediction season has closed. Eleven challenges were released beginning on 3 August 2015, and the final challenge closed on 1 February 2016. Independent assessment of the predictions has been completed.

The CAGI 4 Conference was held 25-27 March 2016 in Genentech Hall on the UCSF Mission Bay campus in San Francisco, California. Conference presentations (remixable slides and video) are provided on the [CAGI 4 conference program page](#) and also on each challenge page.

Please distribute this information widely and follow our Twitter feed @CAGInews and the web site for updates. For more information on the CAGI experiment, see the [Overview](#).

CAGI Lead Scientist or Postdoctoral Researcher position open!

Take the lead of the CAGI experiment! We are searching for a CAGI Lead Scientist or Postdoctoral Researcher to join us in early 2016. Roger Hoskins will lead the CAGI 4 experiment to its completion, but he is unable to continue in the role beyond mid-2016. He will overlap with the new CAGI leader to ensure a seamless transition. Job descriptions posted at <http://compbio.berkeley.edu/jobs>

The P16 challenge

CDKN2A is the most common, high penetrance, susceptibility gene identified to date in **familial malignant melanoma**. **p16^{INK4A}** is one of the two **oncosuppressor** which promotes cell cycle arrest by inhibiting cyclin dependent kinase (CDK4/6).

Challenge: Evaluate how different variants of p16 protein impact its ability to block cell proliferation.

Provide a number between **50%** that represent the normal **proliferation rate of control cells** and **100%** the maximum proliferation rate in case cells.

SNPs&GO prediction


Proliferation rates predicted using the output of SNPs&GO without any optimization.

| Variant | Prediction | Real | Δ | %WT | %MUT |
|---------|------------|-------|-------|-----|------|
| G23R | 0.932 | 0.918 | 0.014 | 84 | 0 |
| G23S | 0.923 | 0.693 | 0.230 | 84 | 1 |
| G23V | 0.940 | 0.901 | 0.039 | 84 | 0 |
| G23A | 0.904 | 0.537 | 0.367 | 84 | 2 |
| G23C | 0.946 | 0.866 | 0.080 | 84 | 0 |
| G35E | 0.590 | 0.600 | 0.010 | 12 | 14 |
| G35W | 0.841 | 0.862 | 0.021 | 12 | 0 |
| G35R | 0.618 | 0.537 | 0.081 | 12 | 4 |
| L65P | 0.878 | 0.664 | 0.214 | 15 | 1 |
| L94P | 0.979 | 0.939 | 0.040 | 56 | 0 |

P16 predictions

SNPs&GO resulted among the best methods for predicting the impact of P16INK4A variants on cell proliferation.

| Method | Q2 | AUC | MC | RMSE | rPearson | rSpearman | rKendallTau |
|--------------------|-------|-------|-------|------|----------|-----------|-------------|
| SPARK-LAB | 0.900 | 0.920 | 0.816 | 0.30 | 0.595 | 0.619 | 0.443 |
| SNPs&GO | 0.700 | 0.880 | 0.500 | 0.33 | 0.575 | 0.616 | 0.445 |
| DrCancer | 0.600 | 0.840 | 0.333 | 0.46 | 0.477 | 0.495 | 0.409 |



The NAGLU challenge

NAGLU is a lysosomal glycohydrolase which deficiency causes a rare disorder referred as Sanfilippo B disease




Challenge: Predict the effect of the 165 variants on NAGLU enzymatic activity.

The submitted prediction should be a numeric value ranging from 0 (no activity) to 1 (wild-type level of activity).

A posteriori evaluation

I performed a posteriori evaluation of the performance based on my version of the predictor and found that **SNPs&GO reaches similar accuracy than the best method (MutPred2)**

| Method | Q2 | AUC | MC | RMSE | rPearson | rSpearman | rKendallTau |
|-----------------------|--------------|--------------|--------------|-------------|--------------|--------------|--------------|
| MutPred2 | 0.780 | 0.850 | 0.565 | 0.30 | 0.595 | 0.619 | 0.443 |
| SNPs&GO | 0.800 | 0.854 | 0.603 | 0.33 | 0.575 | 0.616 | 0.445 |
| SNPs&GO ⁰⁹ | 0.750 | 0.749 | 0.499 | 0.46 | 0.477 | 0.495 | 0.409 |



Conclusions

- The machine learning methods based on sequence and structural information, trained to predict the sign and the value of $\Delta\Delta G$, reach a good level of accuracy.
- Evolutionary information are important for predicting deleterious variants. Wild-type residues in disease-related sites are more conserved than in neutral sites.
- Protein structure information improves performance of machine learning methods to discriminate between disease-causing and neutral variants.
- Nucleotide conservation is an important feature to predict the impact of SNVs in non coding regions

Acknowledgments

Structural Genomics @CNAG

Marc A. Marti-Renom
Francois Serra

Computational Biology and Bioinformatics Research Group (UIB)

Jairo Rocha

Division of Informatics at UAB

Malay Basu
Division Clinical Immunology & Rheumatology
Harry Schroeder
Mohamed Khass

Helix Group (Stanford University)

Russ B. Altman
Jennifer Lahti
Tianyun Liu
Grace Tang

Bologna Biocomputing Group

Rita Casadio
Pier Luigi Martelli
University of Torino
Piero Fariselli
University of Camerino
Mario Compiani

Mathematical Modeling of Biological Systems (University of Düsseldorf)

Markus Kollmann
Linlin Zhao

Other Collaborations

Yana Bromberg, Rutger University, NJ
Hannah Carter, UCSD, CA
Francisco Melo, Universidad Católica, Chile
Sean Mooney, Buck Institute, Novato
Cedric Notredame, CRG Barcelona
Gustavo Parisi, Universidad de Quilmes
Frederic Rousseau, KU Leuven
Joost Schymkowitz, KU Leuven

FUNDING

NIH: 1R21 AI134027- 01A1
MIUR: FFABR
UNIBO: International Cooperation
Startup funding Dept. of Pathology UAB
NIH:3R00HL111322-04S1 Co-Investigator
EMBO Short Term Fellowship
Marie Curie International Outgoing Grant
Marie Curie Reintegration Grant
Marco Polo Research Project
BIOSAPIENS Network of Excellence
SPINNER Consortium

Biomolecules, Folding and Disease

<http://biofold.org/>

